Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 99-107

  Murakami, M ^a,c   Miyamoto, T ^a   Iida, T ^a   Tsukada, H ^a   Watanabe, M ^a   Shida, M ^a   Maeda, H ^a   Nasu, S ^a   Yasuda, S ^a   Yasuda, M ^a   Ide, M ^b  

^a TOKAI UNIVERSITY   (Japan)

^b HIMEDIC Imaging Center at Lake Yamanaka   (Japan)

^c TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

Author keywords

CA125; FDG PET; Recurrent ovarian cancer

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; RETROPERITONEAL CANCER; TITRIMETRY; WHOLE BODY TOMOGRAPHY;

ADENOCARCINOMA; AGED; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TUMOR MARKERS, BIOLOGICAL;

EID: 33645364952     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00471.x     Document Type: Article

References (26)

1. American Cancer Society. Cancer facts & figures 2005. Atlanta, GA American Cancer Society, Inc.
2. Berek JS Trope C Vergote I et al. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999 10 3 7.
3. Markman M. The use of PET scanning in ovarian cancer. Gynecol Oncol 2002 85 391.
4. Meyer T Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000 82 1535 8.
5. Tempany CM Zou KH Silverman SG et al. Staging of advanced ovarian cancer: comparison of imaging modalities - report from the radiological diagnostic oncology group. Radiology 2000 215 761 7.
6. Buist MR Golding RP Burger CW et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994 52 191 8.
7. Schelbert HR Hoh CK Roral HD et al. Procedure guideline for tumor imaging using Fluorine-18-FDG. J Nucl Med 1998 39 1302 5.
8. Yasuda S Ide M Fujii H et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000 83 1607 11.
9. Hubner KH McDonald TW Niethammer JG et al. Assessment of primary andmetastatic ovarian cancer by positron emission tomography (PET) using 2-[18F] deoxyglucose (2-[18F] FDG). Gynecol Oncol 1993 51 197 204.
10. Karlan BY Hawkins R Hoh C et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993 51 175 81.
11. Jimenez-Bonilla J Maldonado A Morales S et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor maker serum levels. Clin Positron Imaging 2000 3 231 6.
12. Nakamoto Y Saga T Ishimori T et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001 176 1449 54.
13. Rose PG Faulhaber P Miraldi F et al. Positron emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001 82 117 21.
14. Grab D Flock F Stohr I et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000 77 454 9.
15. Kubik-Huch RA Dorffler W von Schulthess GK et al. Value of (18F)-FDG position emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000 10 761 7.
16. Yen RF Sun SS Shen YY et al. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001 21 3691 4.
17. Zimmy M Siggelkow W Schroder W et al. 2-[fluorine-18]-fluoro-2-deoxy-d- glucose positron emission tomography in the diagnosis of recurrent cancer. Gynecol Oncol 2001 83 210 315.
18. Makhija S Howden N Edwards R et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002 85 53 8.
19. Bristow RE del Carmen MG Pannu HK et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003 90 519 28.
20. Crute KM Naumann RW Higgins RV et al. The utility of positron emission tomography in ovarian cancer [abstract]. Gynecol Oncol 2002 84 492. Abstract 44.
21. Yoshida Y Kurokawa T Kawahara K et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004 182 227 33.
22. Rubin SC Randal TC Armstrong KA et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999 93 21 4.
23. Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer 2003 13 Suppl. 2 192 5.
24. Niloff JM Knapp RC Lavin PT et al. The CA125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 1986 155 56 60.
25. Maker AP Kristensen GB Bormer OP et al. Is serum CA125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993 49 3 7.
26. Rustin GJ Bast RC Kellofff GJ et al. Use of CA-125 in clinical trial evaluation of new therapic drugs for ovarian cancer. Clin Cancer Res 2004 10 3919 26.